vs
Apellis Pharmaceuticals, Inc.（APLS）与Civeo Corp（CVEO）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Civeo Corp的1.2倍（$199.9M vs $161.6M），Civeo Corp净利率更高（-4.0% vs -29.5%，领先25.5%），Civeo Corp同比增速更快（7.1% vs -5.9%），Civeo Corp自由现金流更多（$14.5M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -1.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
希维欧公司（Civeo Corporation）是一家美国住宿服务跨国企业，从石油国家国际公司（Oil States International）拆分而来，目前是在纽约证券交易所挂牌上市的公众公司，主要为能源等行业项目提供人员住宿配套服务解决方案。
APLS vs CVEO — 直观对比
营收规模更大
APLS
是对方的1.2倍
$161.6M
营收增速更快
CVEO
高出13.0%
-5.9%
净利率更高
CVEO
高出25.5%
-29.5%
自由现金流更多
CVEO
多$28.7M
$-14.3M
两年增速更快
APLS
近两年复合增速
-1.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $161.6M |
| 净利润 | $-59.0M | $-6.5M |
| 毛利率 | — | 22.7% |
| 营业利润率 | -25.6% | -0.1% |
| 净利率 | -29.5% | -4.0% |
| 营收同比 | -5.9% | 7.1% |
| 净利润同比 | -62.2% | 58.1% |
| 每股收益（稀释后） | $-0.40 | $-0.58 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSCVEO
| Q4 25 | $199.9M | $161.6M | ||
| Q3 25 | $458.6M | $170.5M | ||
| Q2 25 | $178.5M | $162.7M | ||
| Q1 25 | $166.8M | $144.0M | ||
| Q4 24 | $212.5M | $151.0M | ||
| Q3 24 | $196.8M | $176.3M | ||
| Q2 24 | $199.7M | $188.7M | ||
| Q1 24 | $172.3M | $166.1M |
净利润APLSCVEO
| Q4 25 | $-59.0M | $-6.5M | ||
| Q3 25 | $215.7M | $-455.0K | ||
| Q2 25 | $-42.2M | $-3.3M | ||
| Q1 25 | $-92.2M | $-9.8M | ||
| Q4 24 | $-36.4M | $-15.4M | ||
| Q3 24 | $-57.4M | $-5.1M | ||
| Q2 24 | $-37.7M | $8.2M | ||
| Q1 24 | $-66.4M | $-5.1M |
毛利率APLSCVEO
| Q4 25 | — | 22.7% | ||
| Q3 25 | — | 25.7% | ||
| Q2 25 | — | 25.3% | ||
| Q1 25 | — | 20.4% | ||
| Q4 24 | — | 18.6% | ||
| Q3 24 | — | 21.4% | ||
| Q2 24 | — | 25.4% | ||
| Q1 24 | — | 21.5% |
营业利润率APLSCVEO
| Q4 25 | -25.6% | -0.1% | ||
| Q3 25 | 48.7% | 4.1% | ||
| Q2 25 | -18.6% | 1.7% | ||
| Q1 25 | -50.0% | -3.8% | ||
| Q4 24 | -12.3% | -6.7% | ||
| Q3 24 | -24.0% | 0.0% | ||
| Q2 24 | -14.7% | 6.9% | ||
| Q1 24 | -36.0% | -1.1% |
净利率APLSCVEO
| Q4 25 | -29.5% | -4.0% | ||
| Q3 25 | 47.0% | -0.3% | ||
| Q2 25 | -23.6% | -2.0% | ||
| Q1 25 | -55.3% | -6.8% | ||
| Q4 24 | -17.1% | -10.2% | ||
| Q3 24 | -29.2% | -2.9% | ||
| Q2 24 | -18.9% | 4.4% | ||
| Q1 24 | -38.5% | -3.1% |
每股收益（稀释后）APLSCVEO
| Q4 25 | $-0.40 | $-0.58 | ||
| Q3 25 | $1.67 | $-0.04 | ||
| Q2 25 | $-0.33 | $-0.25 | ||
| Q1 25 | $-0.74 | $-0.72 | ||
| Q4 24 | $-0.30 | $-1.04 | ||
| Q3 24 | $-0.46 | $-0.36 | ||
| Q2 24 | $-0.30 | $0.56 | ||
| Q1 24 | $-0.54 | $-0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $14.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $174.4M |
| 总资产 | $1.1B | $477.4M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSCVEO
| Q4 25 | $466.2M | $14.4M | ||
| Q3 25 | $479.2M | $12.0M | ||
| Q2 25 | $370.0M | $14.6M | ||
| Q1 25 | $358.4M | $28.4M | ||
| Q4 24 | $411.3M | $5.2M | ||
| Q3 24 | $396.9M | $17.9M | ||
| Q2 24 | $360.1M | $7.4M | ||
| Q1 24 | $325.9M | $16.8M |
总债务APLSCVEO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $43.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSCVEO
| Q4 25 | $370.1M | $174.4M | ||
| Q3 25 | $401.2M | $182.5M | ||
| Q2 25 | $156.3M | $209.4M | ||
| Q1 25 | $164.2M | $220.7M | ||
| Q4 24 | $228.5M | $236.4M | ||
| Q3 24 | $237.1M | $282.2M | ||
| Q2 24 | $264.3M | $297.4M | ||
| Q1 24 | $266.7M | $297.4M |
总资产APLSCVEO
| Q4 25 | $1.1B | $477.4M | ||
| Q3 25 | $1.1B | $491.1M | ||
| Q2 25 | $821.4M | $508.8M | ||
| Q1 25 | $807.3M | $423.8M | ||
| Q4 24 | $885.1M | $405.1M | ||
| Q3 24 | $901.9M | $477.6M | ||
| Q2 24 | $904.5M | $483.2M | ||
| Q1 24 | $831.9M | $513.1M |
负债/权益比APLSCVEO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $19.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $14.5M |
| 自由现金流率自由现金流/营收 | -7.1% | 8.9% |
| 资本支出强度资本支出/营收 | 0.1% | 3.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $2.1M |
8季度趋势，按日历期对齐
经营现金流APLSCVEO
| Q4 25 | $-14.2M | $19.3M | ||
| Q3 25 | $108.5M | $13.8M | ||
| Q2 25 | $4.4M | $-2.3M | ||
| Q1 25 | $-53.4M | $-8.4M | ||
| Q4 24 | $19.4M | $9.5M | ||
| Q3 24 | $34.1M | $35.7M | ||
| Q2 24 | $-8.3M | $32.4M | ||
| Q1 24 | $-133.0M | $6.0M |
自由现金流APLSCVEO
| Q4 25 | $-14.3M | $14.5M | ||
| Q3 25 | $108.3M | $8.2M | ||
| Q2 25 | $4.4M | $-6.8M | ||
| Q1 25 | $-53.4M | $-13.7M | ||
| Q4 24 | $19.3M | $1.8M | ||
| Q3 24 | — | $28.2M | ||
| Q2 24 | $-8.4M | $27.0M | ||
| Q1 24 | $-133.3M | $372.0K |
自由现金流率APLSCVEO
| Q4 25 | -7.1% | 8.9% | ||
| Q3 25 | 23.6% | 4.8% | ||
| Q2 25 | 2.5% | -4.2% | ||
| Q1 25 | -32.0% | -9.5% | ||
| Q4 24 | 9.1% | 1.2% | ||
| Q3 24 | — | 16.0% | ||
| Q2 24 | -4.2% | 14.3% | ||
| Q1 24 | -77.3% | 0.2% |
资本支出强度APLSCVEO
| Q4 25 | 0.1% | 3.0% | ||
| Q3 25 | 0.0% | 3.3% | ||
| Q2 25 | 0.0% | 2.8% | ||
| Q1 25 | 0.0% | 3.7% | ||
| Q4 24 | 0.0% | 5.1% | ||
| Q3 24 | 0.0% | 4.2% | ||
| Q2 24 | 0.0% | 2.8% | ||
| Q1 24 | 0.2% | 3.4% |
现金转化率APLSCVEO
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.93× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CVEO
暂无分部数据
